Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Christmas Comes Early For Bristol: Orencia Approved A Week Before User Fee Date

This article was originally published in The Pink Sheet Daily

Executive Summary

The rheumatoid arthritis agent is expected to be available by the end of February.

You may also be interested in...



Orencia Extension Data Show Two-Year Progression Benefits In RA Patients

Bristol-Myers Squibb says abatacept sustains inhibition of radiographic progression over two years in methotrexate-inadequate responders.

Orencia Extension Data Show Two-Year Progression Benefits In RA Patients

Bristol-Myers Squibb says abatacept sustains inhibition of radiographic progression over two years in methotrexate-inadequate responders.

Repligen Seeks Preliminary Injunction Against Bristol’s RA Therapy Orencia

Repligen says Bristol’s abatacept infringes Repligen’s patent for method of treating rheumatoid arthritis.

Related Content

Topics

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel